^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Anal Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
…the panel added nivolumab and pembrolizumab as preferred options for patients with metastatic anal cancer who have progressed on first-line chemotherapy…
